{"product_id":"alpelisib-plus-fulvestrant-for-pik3ca-mutated-advanced-breast-cancer-final-survival-results-from-the-solar-1-trial-explained-for-patients","title":"Alpelisib Plus Fulvestrant for PIK3CA-Mutated Advanced Breast Cancer: Final Survival Results from the SOLAR-1 Trial Explained for Patients","description":"\u003cp\u003eNew findings from the SOLAR-1 clinical trial show that adding the targeted therapy alpelisib to fulvestrant improved overall survival by nearly 8 months in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer, although this difference did not reach the strict level of statistical significance required by the study design. Patients receiving alpelisib plus fulvestrant lived a median of 39.3 months compared with 31.4 months for those on placebo plus fulvestrant. The combination also significantly delayed the need for chemotherapy, with patients going a median of 23.3 months before starting chemotherapy versus 14.8 months in the placebo group. Importantly, no new safety concerns emerged with longer follow-up, and three times as many patients were still benefiting from treatment after more than three years in the alpelisib group.\u003c\/p\u003e\n\n\u003ch1\u003eAlpelisib Plus Fulvestrant for PIK3CA-Mutated Advanced Breast Cancer: Final Survival Results from the SOLAR-1 Trial Explained for Patients\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eUnderstanding the Basics: What This Study Is About\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#why\"\u003eWhy This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Study Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#findings\"\u003eKey Findings: Survival Results\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#subgroups\"\u003eWho Benefited Most: Subgroup Analyses\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#secondary\"\u003eSecondary Endpoints: Delaying Chemotherapy and Next Treatments\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#safety\"\u003eSafety and Side Effects\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn the SOLAR-1 trial, alpelisib plus fulvestrant improved median overall survival to 39.3 months versus 31.4 months with placebo in PIK3CA-mutated advanced breast cancer.\u003c\/li\u003e\n\u003cli\u003eThe 7.9-month survival gain did not reach the trial's strict statistical significance threshold, but it was consistent with a significant progression-free survival benefit.\u003c\/li\u003e\n\u003cli\u003eAlpelisib delayed the need for chemotherapy by a statistically significant 8.5 months: median time to chemotherapy was 23.3 months versus 14.8 months.\u003c\/li\u003e\n\u003cli\u003ePatients with lung or liver metastases showed a 14.4-month longer median overall survival with alpelisib, though this subgroup analysis was based on small numbers.\u003c\/li\u003e\n\u003cli\u003eSide effects like rash and hyperglycemia were manageable, and only 3% discontinued alpelisib due to adverse events during extended follow-up.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eUnderstanding the Basics: What This Study Is About\u003c\/h2\u003e\n\n\u003cp\u003eBreast cancer is not a single disease, but a collection of different conditions with distinct characteristics. This study focuses on a specific type of advanced breast cancer defined by three features: hormone receptor-positive (HR+), HER2-negative (HER2−), and the presence of a mutation in a gene called \u003cstrong\u003ePIK3CA\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHormone receptor-positive (HR+)\u003c\/strong\u003e means the cancer cells have receptors that bind to estrogen and\/or progesterone, which can fuel cancer growth. \u003cstrong\u003eHER2-negative\u003c\/strong\u003e means the cancer does not have excess amounts of the human epidermal growth factor receptor 2 protein on its surface. Together, HR+\/HER2− advanced breast cancer is the most common subtype of breast cancer.\u003c\/p\u003e\n\n\u003cp\u003eThe \u003cstrong\u003ePIK3CA gene\u003c\/strong\u003e provides instructions for making a protein called p110α, which is a subunit of an enzyme known as phosphatidylinositol-3-kinase (PI3K). This enzyme plays a critical role in cell growth, division, and survival. When PIK3CA is mutated, the PI3K pathway becomes overactive, driving uncontrolled cancer growth.\u003c\/p\u003e\n\n\u003cp\u003ePIK3CA mutations are found in \u003cstrong\u003e28% to 46%\u003c\/strong\u003e of people with HR+, HER2− advanced breast cancer, according to data from multiple studies cited in this article. These mutations are not just common; they are clinically significant. Research has shown they are associated with chemoresistance, meaning the cancer is less likely to respond to chemotherapy, and with a worse overall prognosis.\u003c\/p\u003e\n\n\u003cp\u003eOne study cited in this paper, the SAFIR-02 trial, found that patients with PIK3CA mutations had a median overall survival of \u003cstrong\u003e19.6 months\u003c\/strong\u003e, compared with \u003cstrong\u003e23.5 months\u003c\/strong\u003e for patients without the mutation. This nearly 4-month difference highlights the urgent need for targeted treatments specifically designed for this high-risk population.\u003c\/p\u003e\n\n\u003ch2 id=\"why\"\u003eWhy This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eFor years, the standard approach to treating HR+\/HER2− advanced breast cancer has involved endocrine (hormone) therapy, often combined with other agents. However, when the cancer stops responding to aromatase inhibitors (AIs)—a class of hormone therapy—treatment options become more limited, and the prognosis worsens, particularly for patients with PIK3CA mutations.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAlpelisib\u003c\/strong\u003e (brand name Piqray) is an orally administered, α-selective PI3K inhibitor—a targeted therapy designed to block the overactive PI3K pathway driven by PIK3CA mutations. According to the study, alpelisib is \u003cstrong\u003e50 times more potent\u003c\/strong\u003e against the α isoform of PI3K than against other isoforms, making it a highly specific therapy. In laboratory models, alpelisib has shown a dual mechanism of action: it inhibits PI3K activity and also induces the degradation of the p110α protein in a dose-dependent manner.\u003c\/p\u003e\n\n\u003cp\u003eEarlier results from this same trial, called SOLAR-1, were practice-changing. The primary analysis demonstrated that adding alpelisib to fulvestrant—a medication that blocks and degrades the estrogen receptor—significantly improved \u003cstrong\u003eprogression-free survival (PFS)\u003c\/strong\u003e, which is the time a patient lives without the cancer growing. The median PFS was \u003cstrong\u003e11.0 months\u003c\/strong\u003e with alpelisib plus fulvestrant versus \u003cstrong\u003e5.7 months\u003c\/strong\u003e with placebo plus fulvestrant (hazard ratio [HR] = 0.65; 95% CI, 0.50–0.85; P = 0.00065). The overall response rate (meaning the percentage of patients whose tumors shrank or disappeared) was \u003cstrong\u003e26.6%\u003c\/strong\u003e versus \u003cstrong\u003e12.8%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eHowever, at the time of that initial report, the overall survival data were not yet mature. This paper presents the final, preplanned analysis of overall survival after more than three years of follow-up—the definitive answer to whether the survival benefit matches the progression-free survival benefit.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Study Was Conducted\u003c\/h2\u003e\n\n\u003ch3\u003eTrial Design and Participants\u003c\/h3\u003e\n\n\u003cp\u003eSOLAR-1 was a global, phase 3, prospective, randomized, double-blind, placebo-controlled trial. The study enrolled \u003cstrong\u003epostmenopausal women and men\u003c\/strong\u003e with confirmed estrogen receptor-positive and\/or progesterone receptor-positive, HER2− advanced breast cancer whose disease had progressed while on or after treatment with an aromatase inhibitor. Patients were not allowed to have received prior chemotherapy for advanced disease.\u003c\/p\u003e\n\n\u003cp\u003eA total of \u003cstrong\u003e572 patients\u003c\/strong\u003e were enrolled and divided into two cohorts based on whether a PIK3CA mutation was detected in tumor tissue: the PIK3CA-mutant cohort and the non-mutant cohort.\u003c\/p\u003e\n\n\u003cp\u003eIn the PIK3CA-mutant cohort, \u003cstrong\u003e341 patients\u003c\/strong\u003e were randomized in a 1:1 ratio to receive either:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAlpelisib plus fulvestrant:\u003c\/strong\u003e 169 patients received 300 mg of alpelisib taken orally once daily, combined with 500 mg of fulvestrant given by intramuscular injection\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlacebo plus fulvestrant:\u003c\/strong\u003e 172 patients received a placebo pill plus the same fulvestrant regimen\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFulvestrant was administered on days 1 and 15 of the first 28-day cycle, and then on day 1 of every subsequent 28-day cycle. The dosing schedule allowed for minor adjustments of ±3 days.\u003c\/p\u003e\n\n\u003cp\u003eIn the non-mutant cohort, \u003cstrong\u003e231 patients\u003c\/strong\u003e were randomized similarly (115 to alpelisib plus fulvestrant and 116 to placebo plus fulvestrant). Importantly, treatment crossover from placebo to alpelisib was not permitted at any point during the study.\u003c\/p\u003e\n\n\u003cp\u003ePatients were stratified (grouped) by two factors: the presence of \u003cstrong\u003elung or liver metastases\u003c\/strong\u003e and prior treatment with \u003cstrong\u003eCDK4\/6 inhibitors\u003c\/strong\u003e (a class of targeted therapy commonly used in HR+ breast cancer).\u003c\/p\u003e\n\n\u003cp\u003eEligibility for the mutant cohort required at least one of 11 specific PIK3CA mutations to be detected in tumor tissue. Dose reductions were permitted in the event of severe or intolerable adverse reactions—up to two dose reductions were allowed, though only one was permitted for pancreatitis, after which the patient was discontinued from the study drug.\u003c\/p\u003e\n\n\u003ch3\u003eEndpoints (What the Researchers Measured)\u003c\/h3\u003e\n\n\u003cp\u003eThe primary endpoint of the SOLAR-1 trial was investigator-assessed progression-free survival in the PIK3CA-mutant cohort, which had already been reported. The \u003cstrong\u003ekey secondary endpoint\u003c\/strong\u003e, reported in this paper, was \u003cstrong\u003eoverall survival (OS)\u003c\/strong\u003e in the PIK3CA-mutant cohort—the time from randomization until death from any cause.\u003c\/p\u003e\n\n\u003cp\u003eThe final inferential analysis of OS was prespecified to occur after approximately \u003cstrong\u003e178 deaths\u003c\/strong\u003e were documented. The study was designed with 72% power to detect a true hazard ratio of 0.67, which corresponds to an improvement in median survival from \u003cstrong\u003e30 months\u003c\/strong\u003e (expected in the placebo group) to \u003cstrong\u003e45 months\u003c\/strong\u003e (expected in the alpelisib group) at a one-sided 2.0% level of significance.\u003c\/p\u003e\n\n\u003cp\u003eFor the results to be considered statistically significant, the P-value needed to be ≤ 0.0161, based on an O'Brien-Fleming spending function—a strict statistical boundary designed to control for the possibility of false-positive results while allowing for interim looks at the data.\u003c\/p\u003e\n\n\u003cp\u003eExploratory endpoints included \u003cstrong\u003eprogression-free survival 2 (PFS2)\u003c\/strong\u003e, defined as the time from randomization to disease progression on the first new systemic cancer therapy given after stopping study treatment, or death from any cause. The researchers also performed a \u003cem\u003epost hoc\u003c\/em\u003e (after-the-fact) exploratory analysis of \u003cstrong\u003etime to chemotherapy (TTC)\u003c\/strong\u003e, measuring the time from randomization to the first administration of chemotherapy following discontinuation of study treatment.\u003c\/p\u003e\n\n\u003ch3\u003eAdditional Analyses\u003c\/h3\u003e\n\n\u003cp\u003eAn exploratory survival analysis was also conducted in patients whose PIK3CA mutation was detected in \u003cstrong\u003eplasma circulating tumor DNA (ctDNA)\u003c\/strong\u003e—a liquid biopsy approach that looks for tumor DNA in the blood—regardless of whether they were assigned to the mutant or non-mutant cohort based on tissue testing. This allowed the researchers to validate the tissue-based mutation testing approach against a less invasive blood-based method.\u003c\/p\u003e\n\n\u003ch2 id=\"findings\"\u003eKey Findings: Survival Results\u003c\/h2\u003e\n\n\u003ch3\u003ePatient Disposition: Who Stayed on Treatment Longer\u003c\/h3\u003e\n\n\u003cp\u003eThe data cutoff date for this final analysis was April 23, 2020. The median follow-up from randomization was \u003cstrong\u003e42.4 months\u003c\/strong\u003e (range: 33.1–55.7 months)—meaning the average patient was tracked for more than three and a half years.\u003c\/p\u003e\n\n\u003cp\u003eOne striking finding was the difference in how long patients remained on treatment. At the time of data cutoff:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e21 patients (12.4%)\u003c\/strong\u003e in the alpelisib plus fulvestrant arm were still receiving study treatment\u003c\/li\u003e\n  \u003cli\u003eOnly \u003cstrong\u003e7 patients (4.1%)\u003c\/strong\u003e in the placebo plus fulvestrant arm were still receiving study treatment\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis means \u003cstrong\u003ethree times as many patients\u003c\/strong\u003e were still benefiting from alpelisib-based therapy after more than three years—a meaningful indicator considering these patients had PIK3CA-mutated disease, which is associated with a poor prognosis.\u003c\/p\u003e\n\n\u003cp\u003eThe most common reason for discontinuing treatment was disease progression, which occurred in \u003cstrong\u003e65.7%\u003c\/strong\u003e of patients in the alpelisib arm versus \u003cstrong\u003e80.2%\u003c\/strong\u003e in the placebo arm. Only \u003cstrong\u003e3.0%\u003c\/strong\u003e (5 patients) discontinued due to side effects in the alpelisib arm, compared with \u003cstrong\u003e1.7%\u003c\/strong\u003e (3 patients) in the placebo arm.\u003c\/p\u003e\n\n\u003ch3\u003eOverall Survival: The Main Result\u003c\/h3\u003e\n\n\u003cp\u003eAt the time of this analysis, a total of \u003cstrong\u003e181 deaths\u003c\/strong\u003e had occurred: 87 events (51.5% of patients) in the alpelisib plus fulvestrant arm and 94 events (54.7%) in the placebo plus fulvestrant arm. The median follow-up for overall survival was 30.8 months (range: 0.4–53.4 months).\u003c\/p\u003e\n\n\u003cp\u003eThe headline result was:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian overall survival: 39.3 months\u003c\/strong\u003e (95% CI, 34.1–44.9) with alpelisib plus fulvestrant\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian overall survival: 31.4 months\u003c\/strong\u003e (95% CI, 26.8–41.3) with placebo plus fulvestrant\u003c\/li\u003e\n  \u003cli\u003eThis represents a \u003cstrong\u003e7.9-month numerical improvement\u003c\/strong\u003e in median overall survival\u003c\/li\u003e\n  \u003cli\u003eHazard ratio = 0.86 (95% CI, 0.64–1.15; one-sided P = 0.15)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe prespecified O'Brien-Fleming efficacy boundary of P ≤ 0.0161 was \u003cstrong\u003enot crossed\u003c\/strong\u003e. This means that while the survival difference favored the alpelisib group, the result did not meet the very strict threshold for statistical significance set by the study design. The authors note this was expected given the study was not powered to detect an effect as small as the one observed.\u003c\/p\u003e\n\n\u003cp\u003eFor context, a hazard ratio of 0.86 means that patients in the alpelisib group had a \u003cstrong\u003e14% lower risk of death\u003c\/strong\u003e at any given time point compared with the placebo group. The wide confidence interval (0.64–1.15) indicates substantial uncertainty around this estimate—the true effect could range from a 36% reduction in risk to a 15% increase in risk.\u003c\/p\u003e\n\n\u003cp\u003eDespite not crossing the statistical boundary, the clinical picture is consistent with the earlier progression-free survival benefit. The authors emphasize that these results \"further support the statistically significant prolongation of PFS observed with alpelisib plus fulvestrant in this population.\"\u003c\/p\u003e\n\n\u003ch3\u003eSurvival in Patients with Detectable Mutation in Blood (ctDNA)\u003c\/h3\u003e\n\n\u003cp\u003eAmong patients whose PIK3CA mutation was detected in plasma circulating tumor DNA (a subgroup that included some patients classified as non-mutant by tissue testing), the survival benefit appeared even more pronounced:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian overall survival: 34.4 months\u003c\/strong\u003e (95% CI, 28.7–44.9) with alpelisib plus fulvestrant\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian overall survival: 25.2 months\u003c\/strong\u003e (95% CI, 20.7–29.6) with placebo plus fulvestrant\u003c\/li\u003e\n  \u003cli\u003eHazard ratio = 0.74 (95% CI, 0.51–1.08)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis represents a \u003cstrong\u003e9.2-month improvement\u003c\/strong\u003e in median survival for patients whose mutation was detectable in blood, with a hazard ratio suggesting a 26% reduction in the risk of death.\u003c\/p\u003e\n\n\u003ch2 id=\"subgroups\"\u003eWho Benefited Most: Subgroup Analyses\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers examined overall survival across multiple patient subgroups defined by clinical characteristics. While some of these subgroups were small, making conclusions less reliable, several patterns emerged.\u003c\/p\u003e\n\n\u003ch3\u003ePatients with Lung and\/or Liver Metastases\u003c\/h3\u003e\n\n\u003cp\u003eVisceral metastases (spread to the lung or liver) are associated with a more aggressive disease course and worse outcomes. The analysis showed that this subgroup derived particular benefit from alpelisib:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian overall survival: 37.2 months\u003c\/strong\u003e (95% CI, 28.7–43.6) with alpelisib plus fulvestrant\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian overall survival: 22.8 months\u003c\/strong\u003e (95% CI, 19.0–26.8) with placebo plus fulvestrant\u003c\/li\u003e\n  \u003cli\u003eHazard ratio = 0.68 (95% CI, 0.46–1.00)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis \u003cstrong\u003e14.4-month improvement in median survival\u003c\/strong\u003e is clinically substantial. The hazard ratio of 0.68 indicates a 32% reduction in the risk of death, and the upper boundary of the confidence interval (1.00) just touches the line of no effect, suggesting a borderline but potentially meaningful benefit.\u003c\/p\u003e\n\n\u003ch3\u003eOther Subgroup Findings\u003c\/h3\u003e\n\n\u003cp\u003eThe full breakdown of subgroup analyses revealed variable results:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients without lung\/liver metastases:\u003c\/strong\u003e HR = 1.18 (95% CI, 0.74–1.86)—no benefit observed in this group\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients with bone-only disease:\u003c\/strong\u003e HR = 1.74 (95% CI, 0.83–3.68)—no benefit observed, though this group was small (77 patients)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients without bone-only disease:\u003c\/strong\u003e HR = 0.76 (95% CI, 0.55–1.06)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients with prior CDK4\/6 inhibitor treatment:\u003c\/strong\u003e HR = 0.67 (95% CI, 0.21–2.18)—suggested benefit, but only 20 patients in this subgroup\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients without prior CDK4\/6 inhibitor treatment:\u003c\/strong\u003e HR = 0.87 (95% CI, 0.64–1.18)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEstrogen receptor-positive patients:\u003c\/strong\u003e HR = 0.86 (95% CI, 0.64–1.16)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProgesterone receptor-positive patients:\u003c\/strong\u003e HR = 0.78 (95% CI, 0.55–1.11)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProgesterone receptor-negative patients:\u003c\/strong\u003e HR = 1.07 (95% CI, 0.58–1.99)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients receiving study treatment as first-line therapy:\u003c\/strong\u003e HR = 0.78 (95% CI, 0.51–1.19)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients receiving study treatment as second-line therapy:\u003c\/strong\u003e HR = 0.93 (95% CI, 0.61–1.43)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients with primary endocrine resistance\u003c\/strong\u003e (cancer progressed within 2 years of starting hormone therapy): HR = 0.62 (95% CI, 0.29–1.35)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients with secondary endocrine resistance\u003c\/strong\u003e (cancer progressed after 2 years of hormone therapy): HR = 0.92 (95% CI, 0.65–1.29)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients with sensitive disease\u003c\/strong\u003e to endocrine therapy: HR = 0.82 (95% CI, 0.22–3.14)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients with ECOG performance status 0\u003c\/strong\u003e (fully active): HR = 0.86 (95% CI, 0.59–1.27)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients with ECOG performance status 1\u003c\/strong\u003e (restricted but ambulatory): HR = 0.77 (95% CI, 0.47–1.23)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe authors caution that several subgroups had small numbers of patients, and the results should be interpreted with care. However, the consistent trend toward benefit in patients with lung\/liver metastases, PgR-positive tumors, and those without bone-only disease suggests that specific clinical profiles may predict greater response to alpelisib.\u003c\/p\u003e\n\n\u003ch2 id=\"secondary\"\u003eSecondary Endpoints: Delaying Chemotherapy and Next Treatments\u003c\/h2\u003e\n\n\u003ch3\u003eWhat Happened After Patients Stopped Study Treatment\u003c\/h3\u003e\n\n\u003cp\u003eA total of 148 patients in the alpelisib arm and 164 patients in the placebo arm discontinued study treatment. Among these patients, \u003cstrong\u003e78.4%\u003c\/strong\u003e (116 patients) in the alpelisib arm and \u003cstrong\u003e81.7%\u003c\/strong\u003e (134 patients) in the placebo arm initiated a subsequent cancer therapy.\u003c\/p\u003e\n\n\u003cp\u003eThe types of subsequent treatments received were illuminating:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eChemotherapy-based regimens\u003c\/strong\u003e (including chemotherapy plus hormone therapy) were the most common subsequent treatment in both arms, received by \u003cstrong\u003e50.0%\u003c\/strong\u003e of alpelisib patients and \u003cstrong\u003e56.0%\u003c\/strong\u003e of placebo patients\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHormone therapy-based regimens\u003c\/strong\u003e (including combinations with targeted therapy) were initiated by \u003cstrong\u003e49.1%\u003c\/strong\u003e of alpelisib patients and \u003cstrong\u003e41.8%\u003c\/strong\u003e of placebo patients\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTargeted therapy alone or with hormone therapy\u003c\/strong\u003e was used in \u003cstrong\u003e32.8%\u003c\/strong\u003e (38 patients) of alpelisib patients versus \u003cstrong\u003e27.6%\u003c\/strong\u003e (37 patients) of placebo patients\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCDK4\/6 inhibitors\u003c\/strong\u003e were used in similar proportions: 11.5% (17 patients) in the alpelisib arm versus 13.4% (22 patients) in the placebo arm\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEverolimus\u003c\/strong\u003e was used in 17.2% (20 patients) versus 15.7% (21 patients), respectively\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe fact that fewer patients in the alpelisib arm needed subsequent chemotherapy—and that those who did received it later—suggests the combination provided durable disease control.\u003c\/p\u003e\n\n\u003ch3\u003eProgression-Free Survival on Next Therapy (PFS2)\u003c\/h3\u003e\n\n\u003cp\u003ePFS2 measures the total disease control from randomization through the first subsequent therapy—essentially capturing the benefit of the initial treatment plus the effect of delaying the need for the next line of treatment. By data cutoff, \u003cstrong\u003e118 patients\u003c\/strong\u003e (69.8%) in the alpelisib arm and \u003cstrong\u003e126 patients\u003c\/strong\u003e (73.3%) in the placebo arm had progressed on next therapy or died.\u003c\/p\u003e\n\n\u003cp\u003eMedian PFS2 was:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e22.8 months\u003c\/strong\u003e (95% CI, 18.5–26.3) with alpelisib plus fulvestrant\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e18.2 months\u003c\/strong\u003e (95% CI, 12.8–22.2) with placebo plus fulvestrant\u003c\/li\u003e\n  \u003cli\u003eHazard ratio = 0.80 (95% CI, 0.62–1.03)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis \u003cstrong\u003e4.6-month improvement\u003c\/strong\u003e in PFS2 corresponds to a 20% reduction in the risk of progression or death on subsequent therapy.\u003c\/p\u003e\n\n\u003ch3\u003eTime to Chemotherapy (TTC)\u003c\/h3\u003e\n\n\u003cp\u003eOne of the most clinically meaningful findings was the delay in the need for chemotherapy. In this post hoc analysis:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e95 patients (56.2%)\u003c\/strong\u003e in the alpelisib arm received their first chemotherapy for metastatic disease\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e109 patients (63.4%)\u003c\/strong\u003e in the placebo arm received their first chemotherapy\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian time to chemotherapy: 23.3 months\u003c\/strong\u003e (95% CI, 15.2–28.4) with alpelisib plus fulvestrant versus \u003cstrong\u003e14.8 months\u003c\/strong\u003e (95% CI, 10.5–22.6) with placebo plus fulvestrant\u003c\/li\u003e\n  \u003cli\u003eHazard ratio = 0.72 (95% CI, 0.54–0.95)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePatients in the alpelisib arm went an average of \u003cstrong\u003e8.5 months longer\u003c\/strong\u003e before needing chemotherapy, a statistically significant difference (the confidence interval does not include 1.0). For many patients, delaying chemotherapy is a meaningful quality-of-life benefit, as chemotherapy often comes with more challenging side effects than targeted therapy.\u003c\/p\u003e\n\n\u003ch2 id=\"safety\"\u003eSafety and Side Effects\u003c\/h2\u003e\n\n\u003cp\u003eSafety monitoring continued throughout the extended follow-up period, and the results were reassuring. No new safety signals were observed with longer exposure to alpelisib, and no cumulative (worsening-over-time) toxicity was noted for any adverse event.\u003c\/p\u003e\n\n\u003cp\u003eThe most notable side effect profile:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRash\u003c\/strong\u003e (a group of related skin reactions including rash, maculo-papular rash, dermatitis, and related conditions) occurred in \u003cstrong\u003e54%\u003c\/strong\u003e of patients in the alpelisib plus fulvestrant arm versus \u003cstrong\u003e9%\u003c\/strong\u003e in the placebo plus fulvestrant arm\u003c\/li\u003e\n  \u003cli\u003eHowever, most rash events were \u003cstrong\u003elow grade\u003c\/strong\u003e (grade 1 or grade 2), meaning they were manageable with monitoring and supportive care\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHyperglycemia\u003c\/strong\u003e (elevated blood sugar), a known side effect of PI3K inhibitors, did not increase in frequency with longer time on treatment\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eSide effects were described as generally manageable with close monitoring, administration of additional medications to manage symptoms, and dose modifications when needed. Discontinuation rates due to adverse events were low in both groups: 3.0% in the alpelisib arm and 1.7% in the placebo arm.\u003c\/p\u003e\n\n\u003cp\u003eGiven the timing of the study, the researchers also reported that there were \u003cstrong\u003eno cases of confirmed or suspected COVID-19 infection\u003c\/strong\u003e and no COVID-19-related deaths among the study participants.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThe SOLAR-1 trial provides important, though nuanced, evidence about the long-term benefits of alpelisib in PIK3CA-mutated advanced breast cancer. Several key messages emerge for patients and their oncologists:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFirst, the numeric survival improvement is real and meaningful.\u003c\/strong\u003e The 7.9-month improvement in median overall survival, while not meeting the strict statistical threshold, aligns with the previously demonstrated highly significant progression-free survival benefit. The hazard ratio of 0.86 suggests a 14% reduction in the risk of death, and in certain subgroups—particularly patients with lung or liver metastases—the benefit was considerably larger.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSecond, the delay in chemotherapy is a significant patient-centered benefit.\u003c\/strong\u003e The statistically significant 8.5-month extension in time to chemotherapy (23.3 months versus 14.8 months, HR = 0.72, P \u0026lt; 0.05) means patients spent more than 8 additional months on a well-tolerated oral targeted therapy before needing intravenous chemotherapy. This finding reached statistical significance and represents a concrete quality-of-life advantage.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThird, the PIK3CA mutation matters for treatment selection.\u003c\/strong\u003e Evidence from earlier analyses of SOLAR-1 demonstrated that the benefit of alpelisib was specific to patients with PIK3CA mutations—the proof-of-concept criteria were not met in the non-mutant cohort, confirming that PIK3CA is a predictive biomarker. This means genetic testing of the tumor (and potentially blood) is essential to identify which patients are most likely to benefit from alpelisib.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFourth, longer follow-up confirms the durability of benefit.\u003c\/strong\u003e The fact that 12.4% of patients in the alpelisib arm remained on treatment after 42 months of follow-up—versus just 4.1% in the placebo arm—suggests that a meaningful subset of patients experiences long-term disease control. Given that PIK3CA-mutated disease is associated with a worse prognosis (19.6 months versus 23.5 months in the SAFIR-02 study), any durable benefit is clinically valuable.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinally, the safety profile is acceptable for a chronic therapy.\u003c\/strong\u003e The manageable side effect profile, low discontinuation rates due to adverse events, and absence of cumulative toxicity support the use of alpelisib as a long-term treatment option. Rash and hyperglycemia require monitoring but are generally controllable with standard measures.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations\u003c\/h2\u003e\n\n\u003cp\u003eLike all clinical trials, SOLAR-1 has limitations that patients and clinicians should understand when interpreting these results:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe overall survival analysis did not cross the prespecified statistical significance boundary.\u003c\/strong\u003e The study was designed to detect a 15-month improvement in median survival (from 30 to 45 months), which was more optimistic than the 7.9-month improvement actually observed. The study had only 72% power to detect this larger effect, meaning it was underpowered to detect smaller, still meaningful, survival differences as statistically significant.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCrossover was not permitted, which can bias results in either direction.\u003c\/strong\u003e In some trials, patients in the placebo group are allowed to switch to the experimental treatment after progression. While the lack of crossover here means the observed effect was not diluted, it also means the survival data reflect a pure comparison of initial treatment strategies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe subgroup analyses included small numbers of patients.\u003c\/strong\u003e Several subgroups (e.g., patients with prior CDK4\/6 inhibitor treatment, n = 20; patients with primary endocrine resistance, n = 45) were too small to draw definitive conclusions. The apparent lack of benefit in some subgroups (e.g., bone-only disease) could reflect true biology or simply statistical noise.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe study population was mostly postmenopausal women.\u003c\/strong\u003e Only a small number of men were included, and the results may not fully generalize to premenopausal women or to men with this disease.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients with prior chemotherapy for advanced disease were excluded.\u003c\/strong\u003e The results apply to patients earlier in their treatment course, not those who have already received chemotherapy for metastatic breast cancer.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe time-to-chemotherapy analysis was post hoc\u003c\/strong\u003e, meaning it was not part of the original statistical plan. While the results are compelling, they should be considered exploratory.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe study was conducted before and during the early phase of the COVID-19 pandemic.\u003c\/strong\u003e While no COVID-19 cases were reported, the pandemic could have subtly affected patient follow-up, treatment decisions, or survival data in ways that are difficult to quantify.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on the SOLAR-1 results and the broader body of evidence, here are practical recommendations for patients with advanced breast cancer:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRequest PIK3CA testing.\u003c\/strong\u003e If you have HR+\/HER2− advanced breast cancer, ask your oncologist whether your tumor has been tested for PIK3CA mutations. This can be done on tumor tissue (a biopsy or surgical specimen) and increasingly on blood samples (liquid biopsy using circulating tumor DNA). The finding of a PIK3CA mutation opens the door to alpelisib-based therapy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss alpelisib with your oncologist if you are PIK3CA-mutated.\u003c\/strong\u003e The combination of alpelisib and fulvestrant has demonstrated significant progression-free survival benefits, a numeric overall survival improvement, and a meaningful delay in the need for chemotherapy. This may be an appropriate option if your disease has progressed on or after aromatase inhibitor therapy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand that survival benefit may vary.\u003c\/strong\u003e If your cancer has spread to the lungs or liver, the survival benefit appears particularly substantial (14.4 months in this analysis). Even if you do not have visceral metastases, the progression-free survival benefit and delay in chemotherapy apply broadly.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlan for monitoring.\u003c\/strong\u003e If you start alpelisib, work with your care team to monitor for known side effects, especially rash and elevated blood sugar. Regular blood glucose checks and skin care routines can help manage these issues early, before they become serious.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDo not be discouraged by the statistical nuance.\u003c\/strong\u003e The overall survival result did not meet the very strict statistical bar set by the study design, but the pattern of benefit across multiple endpoints (PFS, PFS2, time to chemotherapy, and the direction of the OS effect) is consistent. Clinical benefit is about more than a single P-value.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about clinical trials.\u003c\/strong\u003e If alpelisib is not an option for your specific situation, ask your oncologist about other clinical trials for PIK3CA-mutated breast cancer, including studies of next-generation PI3K inhibitors and combinations with other targeted agents.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsider a second opinion at a cancer center.\u003c\/strong\u003e Breast cancer treatment is rapidly evolving, and comprehensive cancer centers with expertise in genomic testing may offer additional perspective on the best sequencing of treatments for your specific tumor profile.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is PIK3CA-mutated advanced breast cancer?\u003c\/h3\u003e\n\u003cp\u003eIt is a subtype of hormone receptor-positive, HER2-negative advanced breast cancer that has a mutation in the PIK3CA gene. This mutation occurs in 28% to 46% of patients and is linked to resistance to chemotherapy and a worse overall prognosis, making targeted treatment important.\u003c\/p\u003e\n\u003ch3\u003eWhich patients appeared to benefit most from alpelisib?\u003c\/h3\u003e\n\u003cp\u003eThose with lung or liver metastases had a median overall survival of 37.2 months versus 22.8 months on placebo, a 14.4-month gain. Patients whose PIK3CA mutation was detected in blood also showed a 9.2-month survival improvement, though these subgroup findings come from small numbers.\u003c\/p\u003e\n\u003ch3\u003eWhat are the common side effects of alpelisib plus fulvestrant?\u003c\/h3\u003e\n\u003cp\u003eThe most notable side effect was rash, occurring in 54% of patients on alpelisib versus 9% on placebo, but most cases were low grade and manageable. Elevated blood sugar (hyperglycemia) was also seen. Only 3% of patients stopped alpelisib due to side effects.\u003c\/p\u003e\n\u003ch3\u003eShould I ask my doctor about PIK3CA testing?\u003c\/h3\u003e\n\u003cp\u003eIf you have hormone receptor-positive, HER2-negative advanced breast cancer, asking about PIK3CA testing is reasonable. It can be done on tumor tissue or blood (liquid biopsy). Finding this mutation is necessary to determine if alpelisib-based therapy might be an option for you.\u003c\/p\u003e\n\u003ch3\u003eDoes the survival result mean alpelisib is not effective?\u003c\/h3\u003e\n\u003cp\u003eNo. Although the overall survival improvement was not statistically significant, the trial showed a significant progression-free survival benefit and a significant delay in chemotherapy. The pattern across multiple endpoints supports the value of alpelisib for PIK3CA-mutated disease; discuss with your oncologist.\u003c\/p\u003e\n\u003ch3\u003eIf I have PIK3CA-mutated HR+\/HER2- advanced breast cancer and my oncologist recommends alpelisib plus fulvestrant, when should I get a second opinion?\u003c\/h3\u003e\n\u003cp\u003eA second opinion is reasonable before starting alpelisib plus fulvestrant, particularly to confirm PIK3CA testing was done on tumor tissue or blood, since the benefit of alpelisib was specific to patients with PIK3CA mutations. It is also worth seeking review if you have lung or liver metastases, where median overall survival was 37.2 months versus 22.8 months on placebo, or if you are weighing how long chemotherapy can be delayed. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal Article:\u003c\/strong\u003e \"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1\"\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e F. André, E. M. Ciruelos, D. Juric, S. Loibl, M. Campone, I. A. Mayer, G. Rubovszky, T. Yamashita, B. Kaufman, Y.-S. Lu, K. Inoue, Z. Pápai, M. Takahashi, F. Ghaznawi, D. Mills, M. Kaper, M. Miller, P. F. Conte, H. Iwata, and H. S. Rugo\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e Annals of Oncology, Volume 32, Issue 2, February 2021, pages 208–217. Published online November 25, 2020. DOI: https:\/\/doi.org\/10.1016\/j.annonc.2020.11.011\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eClinical Trial Registration:\u003c\/strong\u003e ClinicalTrials.gov Identifier: NCT02437318\u003c\/p\u003e\n\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not constitute medical advice. Patients should discuss their individual treatment options with their healthcare providers.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47885838975132,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0599\/5449\/5644\/files\/ddn-medical-article-alpelisib-plus-fulvestrant-for-pik3ca-mutated-advanced-breast-cancer-final-survival-results-from-the-solar-1-trial-expla-hero.png?v=1793341321","url":"https:\/\/diagnosticdetectives.com\/products\/alpelisib-plus-fulvestrant-for-pik3ca-mutated-advanced-breast-cancer-final-survival-results-from-the-solar-1-trial-explained-for-patients","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}